Sector News

Pfizer’s John Davis splashes into biotech as Magenta CMO

February 26, 2018
Life sciences

Magenta Therapeutics has appointed a new chief medical officer: John Davis, M.D., who was previously a senior vice president and head of early clinical development at Pfizer.

The startup, which raised $50 million in series B funding last May, is working on targeted therapeutics to make stem cell transplants safer and more effective. It has programs addressing patient preparation for transplants, stem cell harvesting, stem cell expansion and post-transplant complications.

“As a clinical stage company, we are delighted to welcome John, a very seasoned physician-scientist, to our team,” said Magenta CEO Jason Gardner in a statement. “John’s rich experience in immunology and drug development will be crucial as we move our programs forward.”

Before heading early clinical development at Pfizer, Davis served stints at Baxalta and Genentech and spent nearly 10 years on the faculty at UC San Francisco conducting research in autoimmune disease.

Magenta’s lead candidate, MGTA-456, is designed to expand the number of stem cells in cord blood used for transplant. The biotech licensed the drug, formerly known as HSC835, from Novartis in May, gaining the rights to use it in “selected applications.” It is developing the drug for multiple diseases, including immune and blood disorders.

The biotech announced a second deal at the same time, with Be the Match BioTherapies (BTMB), which is working on delivering autologous and allogeneic cellular therapies. The collaboration allows Magenta to use BTMBs’ cell therapy delivery platform, industry relationships, clinical trial design and management, and patient outcomes data.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.